Osteopontin Levels In Patients Research Articles

Beyond prediction: unveiling the prognostic power of μ-opioid and cannabinoid receptors, alongside immune mediators, in assessing the severity of SARS-CoV-2 infection

BackgroundThis study aims to explore the potential of utilizing the expression levels of cannabinoid receptor 2 (CB2), μ-opioid receptor (MOR), MCP-1, IL-17, IFN-γ, and osteopontin as predictors for the severity of SARS-CoV-2 infection. The overarching goal is to delineate the pathogenic mechanisms associated with SARS-CoV-2.MethodsUsing quantitative Real-time PCR, we analyzed the gene expression levels of CB2 and MOR in nasopharynx specimens obtained from patients diagnosed with SARS-CoV-2 infection, with 46 individuals classified as having severe symptoms and 46 as non-severe. Additionally, we measured the circulating levels of MCP-1, IL-17, IFN-γ, and osteopontin using an ELISA assay. We examined the predictive capabilities of these variables and explored their correlations across all patient groups.ResultsOur results demonstrated a significant increase in MOR gene expression in the epithelium of patients with severe infection. The expression of CB2 receptor was also elevated in both male and female patients with severe symptoms. Furthermore, we observed concurrent rises in MCP-1, IL-17, IFN-γ, and osteopontin levels in patients, which were linked to disease severity. CB2, MOR, MCP-1, IL-17, IFN-γ, and osteopontin showed strong predictive abilities in distinguishing between patients with varying degrees of SARS-CoV-2 severity. Moreover, we identified a significant correlation between CB2 expression and the levels of MOR, MCP-1, osteopontin, and IFN-γ.ConclusionsThese results underline the interconnected nature of molecular mediators in a sequential manner, suggesting that their overexpression may play a role in the development of SARS-CoV-2 infections.Graphical

Serum osteopontin levels in patients with psoriasis vulgaris and its relation with oxidative stress

Serum osteopontin levels in patients with psoriasis vulgaris and its relation with oxidative stress

Osteopontin in patients with chronic obstructive pulmonary disease and coronary heart disease

Background: Osteopontin is a protein expressed by various cell types, such as endothelial and epithelial cells, osteoclasts, hepatocytes, smooth muscle cells, activated macrophages, and T-cells. Cardiomyocytes, heart fibroblasts, endothelial cells of coronary arteries express osteopontin in response to hypoxia, inflammation, toxic factors, mechanical strain, and other stimuli.
 Aim: To study osteopontin levels in patients with chronic obstructive pulmonary disease (COPD) depending on concomitant ischemic heart disease (IHD), to identify an association between osteopontin levels with severity of COPD and functional lung test parameters.
 Materials and methods: This open-label, prospective, non-randomized comparative study with parallel groups included 99 patients with COPD grades AD by GOLD, with 49 of them having confirmed comorbid stable IHD. Serum osteopontin levels were measured by immunoenzyme assay (Human Osteopontin Platinum ELISA; Bender MedSystems, Austria). The data is given as medians and quartiles (Me [Q1; Q3]). In all patients we performed functional lung tests with bronchodilation, a 6-minute walking test, BODE index assessment, as well as CAT and mMRC questionnaires were used.
 Results: In the patients with COPD and IHD, the osteopontin levels were higher than in the patients with COPD without IHD (85.55 [46.86; 110.91] vs 55.43 [20.76; 89.64] ng/mL, respectively; p = 0.027). Osteopontin levels in the patients with all COPD grades and IHD were higher than in those without IHD, but the difference was significant only in GOLD grade B patients (91.28 [73.04; 110.91] vs 37.81 [22.54; 82.95] ng/mL, respectively, р = 0.028) and GOLD grade D patients (80.79 [34.65; 111.11] vs 37.46 [13.32; 109.5] ng/mL, respectively, р = 0.027).
 Conclusion: A significant increase of osteopontin levels in comorbid patients with COPD and stable IHD found in this study has not been previously known. It is necessary to perform further studies to identify a threshold level of osteopontin predictive of the risk of COPD exacerbations or cardiovascular events. This would help to improve medical treatment of COPD patients, as well as to identify the risk groups.

Pattern of Serum Osteopontin Level in Patients with Cirrhotic Liver versus Patients with Hepatocellular Carcinoma

Pattern of Serum Osteopontin Level in Patients with Cirrhotic Liver versus Patients with Hepatocellular Carcinoma

Elevated serum osteopontin levels in patients with severe cutaneous adverse drug reactions.

Osteopontin (OPN) was initially described as a protein involved in bone metabolism, but the roles played by OPN in the immune system and allergic reactions have attracted increasing attention. Here, we clarify the OPN-related dynamics of severe cutaneous adverse drug reactions, and assess whether the OPN level has utility for classifying such reactions and serving as a biomarker of severity. Serum OPN levels in patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS), Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and erythema multiforme-type drug reaction (EM-DR) were quantified by ELISA. The OPN sources were analyzed by dual immunofluorescence assay of DIHS, SJS/TEN and EM-DR biopsy specimens. The serum OPN levels of DIHS/DRESS patients (489.1 ± 37.0ng/mL) and SJS/TEN patients (508.5 ± 47.8ng/mL) were significantly higher compared with controls (314.4 ± 14.3ng/mL; p < 0.001). After treatment, the serum OPN level of DIHS/DRESS patients decreased to that of controls. In addition, OPN levels in DIHS/DRESS patients and SJS/TEN patients were higher than in patients with EM-DR (Mann-Whitney U test, p < 0.05). However, when the Kruskal-Wallis test was used to compare the OPN levels among the three groups of patients, the difference was not significant (p=0.055). Dual immunofluorescence assay revealed that T lymphocytes and macrophages were the main OPN sources in DIHS, SJS/TEN and EM-DR patients. These data suggest that the OPN level can be used to evaluate the severity of inflammation in patients experiencing drug reactions.

Serum osteopontin can improve papillary thyroid cancer risk assessment of Bethesda III thyroid nodules: a preliminary study.

Thyroid cancer can be detected in 5-10% of patients with thyroid nodules. Management may be a challenge if fine-needle aspiration biopsy yields Bethesda III findings. Most of these cases undergo surgery and are ultimately found benign. Our aim was to evaluate whether serum osteopontin can accurately estimate thyroid cancer risk in cases with cytologically Bethesda III thyroid nodules and, thereby, decrease the number of unnecessary surgical interventions. We obtained blood samples of cases with repeated cytologically Bethesda III thyroid nodules before surgery, and followed up the pathology results after thyroidectomy. We evaluated serum osteopontin from 36 patients with papillary thyroid cancer and compared them with 40 benign cases. Serum osteopontin levels in patients with papillary thyroid cancer are significantly higher than in benign cases (mean serum osteopontin: 10.48 ± 3.51 ng/mL vs6.14 ± 2.29 ng/mL, P < 0.001). The area under the receiver operating characteristics curve was 0.851, suggesting that serum osteopontin could have considerable discriminative performance. In our preliminary study, high serum osteopontin levels can predict the risk of papillary thyroid cancer in thyroid nodules with Bethesda III cytology. Further studies are necessary to confirm these findings.

Investigation of osteopontin and CD44 levels in patients with temporomandibular joint disorders

BackgroundThe information about the cellular and molecular mechanisms underlying the formation and progression of temporomandibular joint disorders (TMDs) is limited and the etiology of these disorders is still controversial. Biochemical analyzes are an important tool in understanding the pathogenesis of these diseases. ObjectiveThe main aim of the present study was to investigate the role of serum osteopontin (OPN) and CD44 levels in the etiopathology and to determine whether they could be used as biochemical markers in the diagnosis of TMDs. MethodsTotal number of 54 patients who diagnosed with TMD and total of 34 healthy controls with no joint problems were included in this study. Blood samples were obtained from all patients and then serum samples were analyzed by OPN and CD44 enzyme-linked immunosorbent assay (ELISA). ResultsAccording to the control group, there was a significant decrease in OPN levels in patients with TMDs. However, no statistically significant difference was found in CD44 levels among the groups. ConclusionsFindings obtained in the present study suggest that OPN may play a key role in the pathogenesis of TMDs as a novel biomarker in the diagnosis of these diseases.

Osteopontin Levels in Patients with Squamous Metastatic Head and Neck Cancer.

Background and Objectives: Increased osteopontin (OPN) concentrations in the plasma of patients with head and neck squamous cancer (HNSCC) have diagnostic significance, and it can indicate more aggressive biological behavior of cancer. The aim of this study was to determine OPN levels in patients with HNSCC of different primary locations and to assess its prognostic significance in metastasis development. Materials and Methods: This cohort study included 45 patients (41 male and 4 female patients) with HNSCC with different primary localization of head and neck. All patients underwent surgery—neck dissection. All patients were categorized according to the histological findings of the resected material and tumor–node–metastasis (TNM) classification system. After surgery, N categories were determined on the basis of histological features of resected material. Results: The histological findings of our patients showed: N0 in 11 patients, N1 in 8 patients, N2a in 4 patients, N2b in 14 patients and N2c in 8 patients. Plasma OPN values in all study participants ranged from 2.24 to 109.10 ng/mL. OPN levels in plasma of patients with negative nodes compared to the group of patients with positive nodes in the neck differed significantly (16.89 ng/mL to 34.08 ng/mL, respectively; p = 0.03). There were significantly lower OPN plasma levels in the group of subjects with histologically positive one lymph node in the neck (N1) compared to the group of patients with N2b histologically positive findings of resected neck material (10.4 ng/mL to 43.9 ng/mL, respectively; p = 0.02). Conclusions: The results have shown that growing N degrees of positive neck nodes classification were accompanied by growing values of plasma osteopontin. Osteopontin might be important for the development of neck metastases.

Osteopontin Level in Androgenetic Alopecia and Its Relation to Metabolic Disorders

A few past examinations have researched the relationship between factors identified with Metabolic disorder and Androgenetic alopecia. Osteopontin capacities as a favorable to incendiary cytokine where Osteopontin can balance the resistant reaction by upgrading articulation of T aide cytokines and extracellular grid corrupting catalysts. The point of the current investigation was to assess serum Osteopontin level in patients with androgenetic alopecia and appraisal of its clinical criticalness according to metabolic condition segments.This investigation was led on 50 patients experiencing AGA (Group A) notwithstanding 30 evidently sound patients of coordinated age and sex as a benchmark (Group B). Serum Osteopontin and FBS and lipid profile were estimated in all subjects. Mean serum level of Osteopontin in patients' gathering was higher than in control gathering and the thing that matters was measurably huge. There was a factually critical distinction among patients and control bunches with respect to serum level of FBS, fatty substances and LDL cholesterol. Additionally, serum fatty substances level was essentially higher in male than female patients. Serum osteopontin level was fundamentally emphatically associated with BMI, FBS, serum complete cholesterol and serum LDL levels which mirrors its conceivable function in pathogenesis of metabolic problems in AGA patients.

Plasma osteopontin levels in patients with acute kidney injury requiring dialysis: a study in a tertiary care institute in South India.

Osteopontin (OPN) is evolving as a novel biomarker of injury, overall survival and renal outcome in critically ill patients with acute kidney injury (AKI), requiring renal replacement therapy. We performed a prospective study on 35 consecutive patients of acute kidney injury requiring renal replacement therapy (AKIN stage 3). OPN levels were measured in the patients and in the controls. The relation between OPN and the severity of illness and its effect on the AKI and renal outcome were studied. There was a statistically significant elevation of OPN in patients of AKIN stage 3 in comparison to healthy controls (p = 0.001). The Sequential Organ Function Assessment (SOFA) scores were found to be higher in septic group in comparison to non-septic group and it was statistically significant (p = 0.014). There was significant correlation between SOFA scoring and OPN levels suggesting its association with severity (r = 0.382, p = 0.023). In our study, OPN was found to be a valuable marker of severity of injury, its association with sepsis and renal recovery, in patients with acute kidney injury needing renal replacement therapy.

Elevated CHI3L1 and OPN levels in patients with anti-N-methyl-d-aspartate receptor encephalitis

Chitinase-3-like 1 (CHI3L1) and osteopontin (OPN) are known biomarkers of neuroinflammation. Herein, we explored the relationship between these inflammatory markers with the disease severity and prognosis in anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis. We recruited 36 anti-NMDAR encephalitis patients and 20 controls. Compared to the levels in the controls, the cerebrospinal fluid (CSF) and serum levels of CHI3L1 and OPN were significantly increased in patients with anti-NMDAR encephalitis, and the CSF levels were found to be correlated with the initial and 6-month follow-up modified Rankin Scale (mRS) scores and abnormal brain MRI (suggestive of encephalitis). In addition, the CSF levels of CHI3L1 were associated with age, the CSF white blood cell (WBC) count and the CSF/serum albumin index (CSF-AI). CHI3L1 and OPN might serve as promising biomarkers for anti-NMDAR encephalitis.

Plasma osteopontin levels, but not its myocardial expression, reflect heart failure severity in recently diagnosed dilated cardiomyopathy.

Elevated levels of the extracellular matrix glycoprotein osteopontin (OPN) may be detected in both myocardium and plasma under various pathological conditions affecting the heart. Several studies demonstrated increased plasma OPN levels in patients with heart failure due to dilated cardiomyopathy (DCM), while other studies showed high OPN expression levels in the myocardium of such patients. However, very little is known about OPN levels in both plasma and myocardium of the same individual with DCM. Therefore, we aimed to compare plasma OPN levels and levels of myocardial OPN expression in patients with recent-onset DCM (Ro-DCM). We examined plasma OPN as well as creatinine, C‑reactive protein (CRP), brain natriuretic peptide (BNP), and troponinI levels in 25patients with Ro-DCM. Furthermore, all subjects underwent transthoracic echocardiography, selective coronary angiography, and endomyocardial biopsy (EMB) for the assessment of myocardial OPN expression. No significant correlation between myocardial OPN expression and clinical, biochemical, or echocardiographic parameters was found. In log transformation analysis, plasma OPN levels correlated significantly with BNP levels (r = 0.46, p = 0.031), with CRP levels (r = 0.52, p = 0.015), and with early diastolic mitral annular velocity (r = -0.57, p = 0.009). There was aborderline association between the plasma OPN log value and New York Heart Association class (p = 0.053). Plasma OPN levels reflect heart failure severity in patients with Ro-DCM. Myocardial OPN expression is not associated with either plasma OPN levels or markers of heart failure in these individuals.

Osteopontin Levels in Patients With Chronic Kidney Disease Stage 5 on Hemodialysis Directly Correlate With Intact Parathyroid Hormone and Alkaline Phosphatase.

Chronic kidney disease stage 5 (CKD5) marks the fifth stage of renal failure, frequently causing dysregulation of bone and mineral metabolism. Challenges exist in evaluating and managing chronic kidney disease–mineral bone disorder (CKD-MBD) with the standard panel of biomarkers. Our objective was to profile osteopontin (OPN) in patients with CKD5 on maintenance hemodialysis (CKD5-HD) and elucidate its relationship to phosphorus (P), calcium (Ca2+), alkaline phosphatase (AP), and intact parathyroid hormone (iPTH) to improve understanding of the present model of CKD-MBD. Elevation of plasma OPN was seen in the CKD5-HD cohort (n = 92; median: 240.25 ng/mL, interquartile range [IQR]: 169.85 ng/mL) compared to a normal group (n = 49; median: 63.30 ng/mL, IQR: 19.20 ng/mL; p < .0001). Spearman correlation tests revealed significant positive correlations of OPN with iPTH (p < .0001; r = 0.561, 95% confidence interval = 0.397-0.690) and OPN with AP (p < .0001; r = 0.444, 95% confidence interval = 0.245-0.590) in CKD5-HD patients. Ultimately, OPN may play an integral role in the MBD axis, suggesting that it may be important to actively monitor OPN when managing CKD5-HD.

Circulating Levels of Osteopontin in Patients With Psoriasis: A Systematic Review and Meta-Analysis

Background: Both Th1 and Th17 have been proposed to be pathogenically essential in psoriasis. Osteopontin (OPN) is known to enhance Th1 responses, inhibit Th2 ones, and take part in the modulation of Th17 cell lineage. Due to its impact on Th1/Th17 immune responses, several reports have suggested that OPN may be of pathogenic importance in psoriasis. Our objective was to review the literature for studies that have assessed the circulating levels of OPN in psoriatic cases and controls and to meta-analyze the evidence obtainable. Methods: Search was performed in PubMed, Central, and Embase. Eligible were studies that have assessed OPN concentrations in patients with psoriasis and a group of reference. Results: Patients with psoriasis had increased OPN concentrations compared with controls (random-effects model, standardized mean difference: 1.58 ng/mL, 95% confidence interval: 0.90-2.26; P &lt; .0001]). Heterogeneity among studies was high ( I2: 92.2%; P &lt; .0001). The meta-regression analysis showed that the study quality (RTI score) reduced heterogeneity ( I2: 85.2%; P &lt; .005), but not age, body mass index (BMI), Psoriasis Area Severity Index, or matching for BMI. Conclusions: This meta-analysis provided evidence that OPN is involved in the pathogenesis of psoriasis, enlarging the list of cytokines able to stimulate the inflammatory response in this disease.

Serum osteopontin in patients with lung cancer and chronic obstructive pulmonary disease: does the co-existence make the difference?

Osteopontin (OPN) is involved in cancer development and metastasis. Increased sputum OPN was detected in chronic obstructive pulmonary disease (COPD). We evaluated serum OPN levels in patients with lung cancer (LC) and/or COPD and aimed to determine OPN prognostic performance in 1-year mortality in LC and also its diagnostic performance in LC among COPD patients. We recruited 167 LC patients, 85 with concomitant COPD. 28 COPD patients served as control group. OPN levels were higher in LC compared to COPD alone (P=0.017) and higher in COPD and LC compared to COPD alone (P=0.031). No difference was observed in OPN levels between LC and COPD vs. LC without COPD (P=0.171). Serum OPN ≥50.3 ng/mL was an independent predictor of 1-year mortality in LC. OPN levels ≥35 ng/mL could predict the presence of LC among COPD patients. In patients with LC and/or COPD, LC is the major determinant for serum OPN. Serum OPN might be a promising prognostic biomarker of LC and a diagnostic biomarker of LC among COPD patients.

Plasma osteopontin levels in patients with dilated and hypertrophic cardiomyopathy.

Osteopontin (OPN) is an extracellular matrix glycoprotein that plays arole in avariety of cellular activities associated with inflammatory and fibrotic responses. Increased OPN levels in myocardium and plasma have been demonstrated in patients with dilated cardiomyopathy (DCM). However, nothing is known about OPN levels in patients with hypertrophic cardiomyopathy (HCM). Therefore, the aim of our study was to compare plasma OPN levels in patients with these two most common cardiomyopathies. We examined plasma OPN as well as creatinine, C‑reactive protein (CRP), brain-type natriuretic peptide (BNP), and troponinI levels in 64patients with DCM, 43patients with HCM, and 75control subjects. Transthoracic echocardiography was also performed on all cardiomyopathy patients. Plasma OPN levels were significantly elevated in patients with DCM compared with HCM patients (95± 43 vs. 57± 21 ng/ml; p< 0.001) and control subjects (54± 19 ng/ml; p< 0.001); however, there was no difference between HCM patients and control subjects. New York Heart Association (NYHA) classIII orIV disease was more frequently present in DCM patients than in HCM subjects (44 % vs. 2 %, p< 0.0001). In multivariate analysis, BNP and CRP levels together with NYHA class were found to be significant predictors of plasma OPN levels in DCM patients (p= 0.002, p= 0.029, and p< 0.001 for BNP, CRP, and NYHA, respectively). Plasma OPN levels were associated with overall heart failure severity rather than with specific cardiomyopathy subtype in patients suffering from DCM or HCM, respectively.

Plasma level of Osteopontin does not respond to total replacement Surgery in patients with severe Primary knee/Hip Osteoarthritis

ObjectiveTo test the response of Osteopontin levels in patients with knee/hip Osteoarthritis undergoing a replacement surgery. MethodPlasma samples of 30 (16 with knee Osteoarthritis and 14 with hip Osteoarthritis) patients have been collected before and 3 month after a knee/hip replacement in order to investigate the above stated aim of this study. ResultOsteopontin levels did not decrease after 3 months of the surgery. ConclusionOsteopontin levels showed no significant reduction and therefore do not respond to replacement treatment.

Evaluation of Bone Mineral Density in Children with Type I Diabetes Mellitus and Relationship to Serum Levels of Osteopontin.

Type I diabetes mellitus (T1DM) patients are at risk of osteoporosis and fracture due to the osteoblast and osteoclast malfunction. Osteopontin (OPN) as the major non-collagenous bone matrix protein is produced by osteoblasts and osteoclasts and involve in bone resorption, formation and remodeling. To evaluate the serum levels of OPN, bone mineral density (BMD) and correlation in patients with T1DM this study was designed. In this case-control study, 87 children with T1DM and 87 age/sex-matched healthy subjects were enrolled. Blood samples were tested for OPN levels by ELISA. Dual energy X-ray absorptiometry was used to measure BMD. The mean levels of BMD in patients was significantly lower than control group (p<0.0001). There was no significant difference between patients and healthy subjects regarding the levels of OPN. However, in patients with high levels of OPN (mean+1.5 standard deviation) the BMD was significantly lower than other patients (p<0.0001). Totally there was a negative correlation between serum levels of OPN and BMD in patients with T1DM (p<0.016). These results indicated that the BMD in T1DM is less than healthy children and elevated level of OPN in patients could be associated with low BMD. A linear negative correlation between serum OPN and total BMD of T1DM patients compared to control group was noticed in this study indicating that the amount of serum OPN could be effective on BMD and a good predicting factor for osteoporosis in patients.

Clinical Significance of Circulating Osteopontin Levels in Patients With Lung Cancer and Correlation With VEGF and MMP-9

ABSTRACTOsteopontin (OPN) is a multifunctional cytokine involved in carcinogenesis. Serum levels of OPN, vascular endothelial growth factor (VEGF), and matrix metalloproteinase-9 (MMP-9) were measured by ELISA in 90 lung cancer patients. OPN levels were elevated in patients compared to controls (p <.0001). Smokers, patients with worse performance status, and weight loss exhibited higher OPN levels (p =.0012,.00036, and.0003, respectively). Increased OPN levels were associated with worse survival (p =.0018). Finally, OPN levels were positively correlated with both VEGF (p =.0008) and MMP-9 (p <.0001). OPN might serve as a prognostic biomarker, and the positive correlation between OPN and both VEGF and MMP-9 could implicate new insights in tumor angiogenesis.

Osteopontin as a biochemical marker and severity indicator for idiopathic hip osteoarthritis.

A diagnostic evaluation of the severity and progression of hip osteoarthritis (OA) using biochemical markers is lacking in the current medical literature. Osteopontin (OPN) has been proved to correlate with the progression and severity of knee OA. Therefore, the examination of plasma OPN levels in patients with idiopathic hip OA and its correlation with disease severity and progression was necessary. Our study included 21 patients displaying symptomatic severe idiopathic hip OA; the diagnosis of the disease was based on the checklist of the American College of Rheumatology and the severity was evaluated according to the K-L grading (Kellgran and Lawrence score). 14 patients showed radiological changes according K-L grade 3 (66.66%), and 7 patients showed radiological changes according K-L grade 4 (33.33%). We observed a highly statistically significant increase of plasma OPN levels in comparison with normal referenced values, the cut off value for differentiating between normal people and patients with hip OA was 193.6 ng/ml. Furthermore, the mean of plasma OPN levels in idiopathic hip osteoarthritis patients with K-L grade 4 (362.51 ± 83.31 ng/mL) was greater than those with K-L grade 3 (283.41 ± 56.31 ng/mL), the difference being statistically significant. plasma OPN levels are increased in idiopathic hip OA and are correlated with the severity of the disease.